Sp1153
PANEL DISCUSSION
Date
May 21, 2024
Presenters
University of California, Irvine
New York University
Yale University School of Medicine
Tracks
Related Products
EVALUATION OF INFLAMMATORY BOWEL DISEASE ACTIVITY THROUGH EXHALED BIOMARKERS: A NOVEL APPROACH FOR IMMEDIATE AND ACCESSIBLE DISEASE STATUS ASSESSMENT AND TREATMENT PLANNING
BACKGROUND: Novel noninvasive methods for evaluating disease activity in patients with inflammatory bowel disease (IBD) are needed to reduce patient burden of traditional assessments, which can involve lab sample collections for blood and stool tests, bowel preparation, and additional appointments…
AMONG PATIENTS WITH IBD USE OF STATINS IS ASSOCIATED WITH LOWER RISK OF DEVELOPING DE NOVO PRIMARY SCLEROSING CHOLANGITIS
BACKGROUND: Primary sclerosing cholangitis (PSC) is a progressive, cholestatic liver disease without medical cure, that confers a significantly elevated risk of malignancy, acute cholangitis and cirrhosis. Approximately 2-7% of patients with inflammatory bowel disease (IBD) will develop PSC…
IDENTIFYING OVERT SIGNS OF ACUTE GASTROINTESTINAL BLEEDING IN THE ELECTRONIC HEALTH RECORD WITH LARGE LANGUAGE MODELS
Early identification of overt signs of GIB (melena, hematochezia, hematemesis) in hospitalized patients may enable expedited evaluation for inpatient endoscopy…
VITAMIN D DIFFERENTIALLY REGULATES MUCOSAL IMMUNOGLOBULIN BINDING TO GUT MICROBIOTA AND DENDRITIC CELL-B CELL SIGNALING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
BACKGROUND: Loss of immune tolerance to commensal gut bacteria plays a critical role in the pathogenesis of inflammatory bowel disease (IBD). Prior studies have demonstrated that immunoglobulin (Ig) binding to the gut microbiota is altered in IBD and associated with disease activity…
